Search bioRxiv⌕ Search

Biology subjects

Kirkby, M.

Publications and source records attributed to Kirkby, M..

2 recordsLinked to original sources

Exploring Differences in Functional Connectivity in Australian Rules Football Players : A Resting-State fMRI Study on the Default Mode Network

The effects of non-concussive impacts in contact-sports such as in Australian rules football (ARF) are still largely unexplored. These impacts are often but not always lower in intensity, but occur more frequently than actual concussions. Since non-concussive impacts are often asymptomatic, their significance may be underestimated. Acute or subacute measurement of non-concussive injury is challenging as the pathological response and injury is poorly described. There is therefore a need for a greater understanding of the pathological consequences of exposure. Growing evidence indicates that resting-state functional connectivity (rs-fMRI) changes in the Default Mode Network (DMN) may be an important biomarker that is sensitive to characterize these impacts. In this work, we examined functional connectivity changes within the DMN of ARF players to evaluate its potential as an early biomarker for non-concussive impacts. Based on rs-fMRI, we compare the DMN of 47 sub-elite ARF players (mean age 21.5{+/-}2.7 years [SD], males 57%) and 42 age-matched healthy controls (mean age 23.2{+/-}2.3 years [SD], males 48%) using Independent Component Analysis (ICA) and Dual Regression. This approach permits an unbiased decomposition of brain activity into networks with principled handling of statistical error. An 83% increase in DMN connectivity (as measured by the Strictly Standardized Mean Difference on values derived from Dual Regression) was observed in ARF players in the left retrosplenial cingulate cortex compared to healthy controls (FDR-corrected p-value from dual regression = 0.03, 95% CI computed via bootstrapping was 58% to 116%). The AUC for distinguishing ARF players from controls was 0.80 (95% CI; [0.71, 0.89]), equating to a PPV of 78% and a NPV of 74%. These results are preliminary; future work could investigate robustness to different random initializations of ICA and validate the findings on an independent testing set, as well as investigate longitudinal changes in ARF players over the course of a playing season.

neuroscience↗

Nanoparticles co-delivering siRNA and mRNA for simultaneous restoration and silencing of gene/protein expression in vitro and invivo

RNA-based agents such as siRNA, miRNA, and mRNA can selectively manipulate gene expression/proteins and have the potential to revolutionize the current therapeutic strategies for various diseases, including cancer. To address the poor stability and inherent limitations of RNA agents, nanoparticle (NP) platforms have been developed to deliver functional mRNA or siRNA inside the cells. Recent studies have focused on either siRNA to knock down proteins causing drug resistance or mRNA technology to introduce tumor suppressors. However, complex diseases like cancer need multi-targeted approaches to selectively target multiple gene expressions/proteins. In this proof-of-concept study, we developed co-delivery nanoparticles containing Luc-mRNA and siRNA-GFP as model RNA agents ((M+S)-NPs) and assessed their effects in vitro and in vivo. Our studies show that NPs can effectively deliver both functional mRNA and siRNA together, simultaneously impacting the expression of two genes/proteins in vitro. Additionally, after in vivo administration, co-delivery NPs successfully knocked down GFP while introducing luciferase in a TNBC mouse model, indicating our NPs have the potential to develop RNA-based anticancer therapeutics. These studies pave the way to develop RNA-based, multitargeted, multi-delivery approaches for complex diseases like cancer. TOC O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=90 SRC="FIGDIR/small/600196v1_ufig1.gif" ALT="Figure 1"> View larger version (37K): org.highwire.dtl.DTLVardef@1668ae2org.highwire.dtl.DTLVardef@1283491org.highwire.dtl.DTLVardef@9336daorg.highwire.dtl.DTLVardef@f654c5_HPS_FORMAT_FIGEXP M_FIG C_FIG

bioengineering↗